Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 16/20 | 0.59 |
| ▸ | TTK | P33981 | 1/20 | 0.57 |
| ▸ | IGF1R | P08069 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25295138 | 0.89 | LRRK2 (0.74) | LRRK2TTKIGF1R | |
| SCHEMBL30523064 | 0.89 | LRRK2 (0.74) | LRRK2TTKIGF1R | |
| SCHEMBL25820487 | 0.88 | LRRK2 (0.59) | LRRK2IGF1R | |
| SCHEMBL25257127 | 0.88 | LRRK2 (0.59) | LRRK2TTKIGF1R | |
| SCHEMBL30523077 | 0.88 | LRRK2 (0.59) | LRRK2TTKIGF1R | |
| SCHEMBL25820519 | 0.87 | LRRK2 (0.59) | LRRK2 | |
| SCHEMBL30229572 | 0.87 | LRRK2 (0.59) | LRRK2 | |
| SCHEMBL25820482 | 0.86 | LRRK2 (0.58) | LRRK2TTKIGF1R | |
| SCHEMBL30956156 | 0.85 | LRRK2 (0.70) | LRRK2TTK | |
| SCHEMBL25820572 | 0.85 | LRRK2 (0.70) | LRRK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4129994-A1 | NOVEL PYRIMIDINE DERIVATIVE, AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND CANCER, COMPRISING SAME | Whan In Pharmaceutical Co., Ltd. (KR) | 2023-02-08 | — | — | EP | claimed |
| US-20240254103-A9 | NOVEL PYRIMIDINE DERIVATIVE, AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND CANCER, COMPRISING SAME | WHAN IN PHARMACEUTICAL CO., LTD. (KR) | 2024-08-01 | — | — | US | disclosed |
| US-20230219930-A1 | NOVEL PYRIMIDINE DERIVATIVE, AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND CANCER, COMPRISING SAME | WHAN IN PHARMACEUTICAL CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219930-A1 | NOVEL PYRIMIDINE DERIVATIVE, AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND CANCER, COMPRISING SAME | WHAN IN PHARMACEUTICAL CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219930-A1 | NOVEL PYRIMIDINE DERIVATIVE, AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND CANCER, COMPRISING SAME | WHAN IN PHARMACEUTICAL CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254103-A9 | NOVEL PYRIMIDINE DERIVATIVE, AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND CANCER, COMPRISING SAME | LRRK2, PARK7, SLC29A2 | LRRK2 1/4885TTK 893/4885IGF1R 3517/4885 |
| US-20230219930-A1 | NOVEL PYRIMIDINE DERIVATIVE, AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND CANCER, COMPRISING SAME | LRRK2, PARK7, SLC29A2 | LRRK2 1/4885TTK 893/4885IGF1R 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.